Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Large Cell, Undifferentiated Or Poorly Differentiated Stage IV Carcinoma of the Lung
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 10 Dec 2017 Status changed from active, no longer recruiting to discontinued.
- 26 Oct 2008 Planned end date changed from 1 Jan 2008 to 1 Dec 2000 as reported by ClinicalTrials.gov.
- 18 Apr 2008 Status change from recruiting to in progress, according to clinicaltrials.gov.